Peerage Pharma Profile
Key Indicators
- Authorised Capital ₹ 0.20 M
as on 24-10-2024
- Paid Up Capital ₹ 0.10 M
as on 24-10-2024
- Company Age 19 Year, 11 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 1.84 Cr
as on 24-10-2024
- Revenue 11.80%
(FY 2023)
- Profit 13.62%
(FY 2023)
- Ebitda 5.79%
(FY 2023)
- Net Worth 20.82%
(FY 2023)
- Total Assets -4.30%
(FY 2023)
About Peerage Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.20 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹1.84 Cr.
Latif Wani, Adil Zargar, Maimona Akhtar, and Two other members serve as directors at the Company.
- CIN/LLPIN
U24232CH2005PTC027847
- Company No.
027847
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
17 Jan 2005
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Chandigarh
Industry
Company Details
- Location
Chandigarh, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Peerage Pharma?
Board Members(5)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Latif Wani  | Director | 17-Jan-2005 | Current |
| Adil Zargar | Director | 17-Jan-2005 | Current |
| Maimona Akhtar | Director | 04-Mar-2015 | Current |
| Aqib Wani | Director | 01-Sep-2018 | Current |
| Saquib Latif | Director | 08-Sep-2018 | Current |
Financial Performance of Peerage Pharma.
Peerage Pharma Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 11.8% increase. The company also saw a substantial improvement in profitability, with a 13.62% increase in profit. The company's net worth Soared by an impressive increase of 20.82%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Peerage Pharma?
In 2023, Peerage Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
The Jammu And Kashmir Bank Limited Creation Date: 09 Jul 2018 | ₹1.49 Cr | Open |
Union Bank Of India Creation Date: 21 May 2013 | ₹3.50 M | Open |
How Many Employees Work at Peerage Pharma?
Peerage Pharma has a workforce of 2 employees as of Apr 08, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Peerage Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Peerage Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
